FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib
Executive Summary
Merck's Arcoxia is linked to an increase in cardiovascular adverse events across multiple analyses, FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review
You may also be interested in...
Prexige Still Postponed: Novartis To Resubmit COX-2 Inhibitor In U.S. In 2007
Novartis plans to resubmit Prexige (lumiracoxib) in the U.S. in the first half of 2007; approval of the oral COX-2 inhibitor in the European Union and Canada for treatment of osteoarthritis symptoms was announced Nov. 7
Prexige Still Postponed: Novartis To Resubmit COX-2 Inhibitor In U.S. In 2007
Novartis plans to resubmit Prexige (lumiracoxib) in the U.S. in the first half of 2007; approval of the oral COX-2 inhibitor in the European Union and Canada for treatment of osteoarthritis symptoms was announced Nov. 7
Merck Arcoxia MEDAL Results Will Likely Not Meet FDA Gold Standard
Despite the release of positive results from a long-term cardiovascular safety trial of its Vioxx follow-on Arcoxia, Merck will likely need to conduct additional studies before receiving FDA approval of the COX-2 inhibitor